基于指甲的代谢学揭示了与阿尔茨海默病进展相关的多德卡诺酸的逐步下降
Wenbo Zhang1, Jiani Wu1, Zhangjing Deng1
1Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Journal of advanced research
|August 3, 2025
概括
手指指甲中的多德卡诺酸可以帮助检测阿尔茨海默病 (AD) 的进展. 较低的水平表明更大的认知障碍,为AD诊断和监测提供了一个新的非侵入性生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 代谢学 代谢学 代谢学
背景情况:
- 指甲代谢学提供了一种非侵入性的方法来追踪长期的生化变化.
- 这种方法可以识别阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 的生物标志物.
研究的目的:
- 研究指甲代谢物作为AD和MCI的生物标志物的潜力.
- 确定与认知衰退和疾病严重程度相关的特定代谢物.
主要方法:
- 收集了199名参与者在不同认知状态 (CDR分数) 的指甲切片.
- 利用气体染色学-质谱学基础的代谢分析来识别差异表达代谢物 (DEM).
- 应用统计和机器学习方法进行分析,包括路径丰富和相关性分析.
主要成果:
- 确定了30个DEM,其中多德卡诺酸显示与AD严重程度相关的显著下降 (CDR 0-3).
- 在调整了混杂因素后,多德卡诺酸水平仍然与疾病严重程度独立相关.
- 一个结合29个DEM的机器学习模型在将参与者分为正常认知,MCI或AD组的分类中取得了67.2%的准确性,其中多德卡诺酸是主要贡献者.
结论:
- 多德卡诺酸是阿尔茨海默病的一个有前途的生物标志物,反映了脂肪酸代谢中断.
- 指甲代谢学为早期AD诊断,分期和监测提供了一个可扩展的,非侵入性的策略.
更多相关视频
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
667
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.5K
相关概念视频
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262